I

Inno-Gene SA
WSE:IGN

Watchlist Manager
Inno-Gene SA
WSE:IGN
Watchlist
Price: 5.04 PLN -0.4% Market Closed
Market Cap: 17.7m PLN
Have any thoughts about
Inno-Gene SA?
Write Note

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

High Profitability Stocks
Life Sciences Tools & Services Industry

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Inno-Gene SA

Revenue
462k PLN
Cost of Revenue
-666k PLN
Gross Profit
-204k PLN
Operating Expenses
-2.4m PLN
Operating Income
-2.6m PLN
Other Expenses
-3.5m PLN
Net Income
-6.1m PLN

Margins Comparison
Inno-Gene SA Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
PL
Inno-Gene SA
WSE:IGN
17.7m PLN
-44%
-566%
-1 326%
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
55%
14%
9%
US
Thermo Fisher Scientific Inc
NYSE:TMO
207.5B USD
41%
17%
14%
US
Danaher Corp
NYSE:DHR
173.4B USD
60%
21%
18%
KR
Samsung Biologics Co Ltd
KRX:207940
70.2T KRW
50%
31%
24%
CH
Lonza Group AG
SIX:LONN
40.8B CHF
29%
13%
9%
US
IQVIA Holdings Inc
NYSE:IQV
39.2B USD
35%
14%
9%
US
Agilent Technologies Inc
NYSE:A
38.5B USD
55%
25%
22%
US
Mettler-Toledo International Inc
NYSE:MTD
26.5B USD
59%
28%
21%
US
Illumina Inc
NASDAQ:ILMN
23.7B USD
64%
7%
-36%
US
West Pharmaceutical Services Inc
NYSE:WST
23.6B USD
35%
20%
17%
Country PL
Market Cap 17.7m PLN
Gross Margin
-44%
Operating Margin
-566%
Net Margin
-1 326%
Country US
Market Cap 1.3T USD
Gross Margin
55%
Operating Margin
14%
Net Margin
9%
Country US
Market Cap 207.5B USD
Gross Margin
41%
Operating Margin
17%
Net Margin
14%
Country US
Market Cap 173.4B USD
Gross Margin
60%
Operating Margin
21%
Net Margin
18%
Country KR
Market Cap 70.2T KRW
Gross Margin
50%
Operating Margin
31%
Net Margin
24%
Country CH
Market Cap 40.8B CHF
Gross Margin
29%
Operating Margin
13%
Net Margin
9%
Country US
Market Cap 39.2B USD
Gross Margin
35%
Operating Margin
14%
Net Margin
9%
Country US
Market Cap 38.5B USD
Gross Margin
55%
Operating Margin
25%
Net Margin
22%
Country US
Market Cap 26.5B USD
Gross Margin
59%
Operating Margin
28%
Net Margin
21%
Country US
Market Cap 23.7B USD
Gross Margin
64%
Operating Margin
7%
Net Margin
-36%
Country US
Market Cap 23.6B USD
Gross Margin
35%
Operating Margin
20%
Net Margin
17%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Inno-Gene SA Competitors

Country Company Market Cap ROE ROA ROCE ROIC
PL
Inno-Gene SA
WSE:IGN
17.7m PLN
-120%
-83%
-49%
-71%
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
3%
2%
3%
3%
US
Thermo Fisher Scientific Inc
NYSE:TMO
207.5B USD
13%
6%
9%
7%
US
Danaher Corp
NYSE:DHR
173.4B USD
8%
5%
6%
5%
KR
Samsung Biologics Co Ltd
KRX:207940
70.2T KRW
10%
6%
11%
7%
CH
Lonza Group AG
SIX:LONN
40.8B CHF
6%
3%
6%
5%
US
IQVIA Holdings Inc
NYSE:IQV
39.2B USD
22%
5%
11%
9%
US
Agilent Technologies Inc
NYSE:A
38.5B USD
25%
13%
18%
17%
US
Mettler-Toledo International Inc
NYSE:MTD
26.5B USD
-648%
24%
49%
29%
US
Illumina Inc
NASDAQ:ILMN
23.7B USD
-37%
-18%
4%
4%
US
West Pharmaceutical Services Inc
NYSE:WST
23.6B USD
18%
13%
18%
17%
Country PL
Market Cap 17.7m PLN
ROE
-120%
ROA
-83%
ROCE
-49%
ROIC
-71%
Country US
Market Cap 1.3T USD
ROE
3%
ROA
2%
ROCE
3%
ROIC
3%
Country US
Market Cap 207.5B USD
ROE
13%
ROA
6%
ROCE
9%
ROIC
7%
Country US
Market Cap 173.4B USD
ROE
8%
ROA
5%
ROCE
6%
ROIC
5%
Country KR
Market Cap 70.2T KRW
ROE
10%
ROA
6%
ROCE
11%
ROIC
7%
Country CH
Market Cap 40.8B CHF
ROE
6%
ROA
3%
ROCE
6%
ROIC
5%
Country US
Market Cap 39.2B USD
ROE
22%
ROA
5%
ROCE
11%
ROIC
9%
Country US
Market Cap 38.5B USD
ROE
25%
ROA
13%
ROCE
18%
ROIC
17%
Country US
Market Cap 26.5B USD
ROE
-648%
ROA
24%
ROCE
49%
ROIC
29%
Country US
Market Cap 23.7B USD
ROE
-37%
ROA
-18%
ROCE
4%
ROIC
4%
Country US
Market Cap 23.6B USD
ROE
18%
ROA
13%
ROCE
18%
ROIC
17%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top